AdipoLABs, a specialist in hyperthermia high frequency cancer treatment, announced on the 6th that it had signed an export contract with the United World Halal Development (UNWHD) to establish a joint venture in India.

AdipoLABs and UNWHD have decided to establish a joint venture to export Adipolabs' hyperthermia high frequency cancer treatment device 'REMISSION 1°C' to India and elsewhere. This joint venture will be established in Chennai, India. There will be a space for the demonstration center, a technical support center, and an education center for the product 'REMISSION 1°C'.

Hana Financial Investment Co., Ltd. decided to cooperate and advise as a Korean financial supervisor. The signing ceremony for the joint venture and export contract was held at the Hana Financial Investment headquarters meeting room in Yeouido, Seoul.

At the signing ceremony, Lee Jin-guk, President of Hana Financial Investment, Han Sung-ho, AdipoLABs' CEO, and Mohamed Jinna, President of the United World Halal Development, attended. According to the agreement, the export contract is about $ 60 million.

Lee Jin-guk, president of Hana Investment Corp., said, "We are happy to help Korean companies with excellent technology to make inroads into overseas markets." "With this business agreement, we will speed up the finance-related business in Islamic world." he said.

Han Sung-ho, CEO of AdipoLABs, said, "Now, the cancer patients in different countries can rely on REMISSION 1°C for their treatment." "Expectations are high as export consultations are being discussed with other countries."

Mohammed Jinna, founding chairman of the United World Halal Development, said, “After myself being directly treated with the 'REMISSION 1°C' in May, we have concluded this contract after sufficient consultation with medical staff in Singapore and India.” "I sincerely hope all cancer patients around the world live a healthy life from now on."

'REMISSION 1°C' is a hyperthermia high frequency medical device that activates NK cells (natural killer immune cells) by raising the body temperature to treat cancer. This year, REMISSION 1°C has received the proper Halal Certification. It also has been registered at the US Food and Drug Administration.

Officials are taking commemorative photos at the opening ceremony of the 'REMISSION 1°C' Indian joint venture and the signing of the export contract held at Hana Financial Investment in Seoul on May 5. (From left) Han Sung-ho, CEO of AdipoLABs, Founder of UNWHD, Mohammed Jinna, Jin-guk Lee, President of Hana Financial Investment / Photo courtesy of AdipoLABs